März 04, 2026
Series

Why the Rules of Medtech Are Beginning to Shift — and What It Could Mean for the Industry

The rules of the medtech industry are quietly beginning to shift. Developments that have been unfolding in the background for years are now starting to influence strategic decisions across the sector — from manufacturers and suppliers to investors and regulators.

A new analysis series by Sandra Heeg, Editor-in-Chief of MedTech Media Europe

 

Many of these changes are already visible. Yet their broader implications for the industry are still widely underestimated.

This new analysis series explores several developments that are likely to shape the medtech industry in the years ahead.

In the coming weeks, the series will examine questions such as:

Part 1 – A problem that becomes visible only after approval

Why key challenges associated with AI-based medical devices often emerge only once products are already on the market

Part 2 – When technology suddenly becomes regulation

Why new rules for intelligent systems could turn into a strategic issue for the medtech industry

Part 3 – Products coming under renewed scrutiny

Why many medical technologies could face renewed evaluation in the coming years

Part 4 – A quiet competition behind the industry

Why a previously underestimated resource may increasingly determine innovation capacity

Part 5 – When security becomes a regulatory issue

Why new risks related to connected medical devices are moving into the focus of regulators

Part 6 – When devices begin to fundamentally change

Why the traditional concept of medical devices is gradually evolving

Part 7 – Production strategies under reconsideration

Why manufacturers are increasingly reassessing their global production footprints

Part 8 – A changing talent market for the industry

Why medtech companies are suddenly competing for very different skill sets

Part 9 – A risk emerging from outside the industry

Why the next bottleneck for medtech could originate in an unexpected sector

The first article in the series will be published shortly. It addresses a question many manufacturers may currently underestimate: why key challenges associated with AI-based medical devices often emerge only after market approval.

 

Author: Sandra Heeg

© 2026 Sandra Heeg. All rights reserved. Copyright retained by the author. Publication on medtechmediaeurope.com is permitted by the author and may be withdrawn at any time.